Nl-Fr

View abstract

This abstract is assigned to session Poster Session - On Display Posters nr 200 ... 299
Presentation preference Poster presentation
TitleIbrutinib-related uveitis: A case series from two tertiary centres in the United Kingdom
PurposeIbrutinib is a Bruton’s tyrosine kinase inhibitor that is licensed for treatment of low-grade B-cell malignancies. A Few case reports in the literature suggest that uveitis may be a side effect of ibrutinib treatment.
MethodsWe report nine cases of ibrutinib-related uveitis from two tertiary centres in the United Kingdom.
ResultsIn our case series, uveitis appears to be a type D, or delayed drug reaction of ibrutinib. The uveitis can be anterior, intermediate, posterior or panuveitis and associated with cystoid macular oedema. It can range in severity from mild, to severe and vision threatening.
ConclusionIbrutinib related uveitis appears to be more common than previously recognised.
Conflict of interestNo
Authors 1
Last nameIBRAHIM
first name(s)H
DepartmentSt Paul’s Eye Unit, Liverpool University Hospitals NHS Trust
CityLiverpool
CountryUnited Kingdom
Authors 2
Last nameKalakonda
first name(s)AJM
DepartmentClatterbridge Cancer Centre NHS Trust
CityLiverpool
CountryUnited Kingdom
Authors 3
Last nameChean
first name(s)CS
DepartmentUniversity Hospitals of Leicester NHS Trust
CityLeicester
CountryUnited Kingdom
Authors 4
Last nameKwan
first name(s)J
DepartmentUniversity Hospitals of Leicester NHS Trust
CityLeicester
CountryUnited Kingdom
Authors 5
Last nameKumar
first name(s)P
DepartmentUniversity Hospitals of Leicester NHS Trust
CityLeicester
CountryUnited Kingdom
Authors 6
Last nameWilliams
first name(s)S
DepartmentClatterbridge Cancer Centre NHS Trust
CityLiverpool
CountryUnited Kingdom
Authors 7
Last nameBeare
first name(s)NAV
DepartmentSt Paul’s Eye Unit, Liverpool University Hospitals NHS Trust
CityLiverpool
CountryUnited Kingdom